Abstract
Atherosclerosis is a progressive disease driven by dyslipidemia, endothelial dysfunction, inflammation, oxidative stress, and vascular cell dysfunction. Extracellular vesicles (EVs) contribute to atherosclerotic pathogenesis by regulating intercellular communication, inflammatory responses, endothelial function, and vascular smooth muscle cell phenotypic switching. Premature mortality of the population and consequences in the form of cardiovascular diseases as well as early disability necessitate the search for new approaches to the treatment of atherosclerosis. Mesenchymal stem cells (MSCs) possess immunosuppressive, regenerative and atheroprotective effects, and MSCs that were preconditioned with cytokines and hypoxia are believed to have a more enhanced effect. Preclinical studies in animal models of atherosclerosis demonstrate that MSC-derived EVs can reduce lesion burden and inflammation in the early phase of atherosclerosis. However, small group sizes, heterogeneous methods of isolation of EVs and dosing, and the lack of tests in advanced lesions limit these findings. It is becoming evident that attempts are being made to utilize EVs for the treatment of cardiovascular diseases. However, the clinical studies reviewed here do not report specific results regarding the use of such EVs, which complicates a deeper understanding of this subject. It can be hypothesized that, perhaps due to a lack of sufficient clinical research, the use of EVs for human atherosclerosis has not yet been explored. Furthermore, several critical factors remain to be considered, including: the source of the MSCs from which EVs are isolated; the genetic profile and the presence of chronic conditions in the donor; the culture system of MSCs; the culture media (specifically the absence of components of animal origin); the parameters of the EVs’ isolation method; and the route of administration of the EVs into the body, as well as their subsequent elimination. In this review, we considered the therapeutic perspective of MSCs and MSC-derived EVs, compiled the preclinical and clinical trials in accordance with disease category and mentioned the aspects of using EVs before clinical translation.